Bit.bio finally details cell therapy pipeline for regenerative treatment, with initial focus on liver

Ayisha Sharma

News Reporter

Bit.bio has lifted the curtain on its early pipeline of regenerative medicine candidates made using its cell programming technology, which is intended to deterministically transform stem cells into mature cells.

The UK-based company’s lead cell therapy program, bbHEP01, comprises encapsulated hepatocyte-like cells made using its opti-ox technology. Bit.bio had previously expressed ambitions to move into cell therapy R&D using opti-ox but had not unveiled the specifics of its pipeline.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Bit.bio finally details cell therapy pipeline for regenerative treatment, with initial focus on liver

Ayisha Sharma

News Reporter

Unlock this article instantly by becoming a free subscriber.

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

Teva to close additional manufacturing sites as it enters next phase of 'pivot to growth'

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

AstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future commercial demand'

Medical Affairs: The Critical Link Between Science, Physicians and Patients

Bit.bio fi­nal­ly de­tails cell ther­a­py pipeline for re­gen­er­a­tive treat­ment, with ini­tial fo­cus on liv­er

Ayisha Sharma

News Reporter

Unlock this article instantly by becoming a free subscriber.

Af­ter eight years with Sanofi, Frank Nes­tle de­parts as CSO, glob­al head of re­search

In­side CVS Care­mark’s move that broke Hu­mi­ra’s hold on the mar­ket

Te­va to close ad­di­tion­al man­u­fac­tur­ing sites as it en­ters next phase of 'piv­ot to growth'

Af­ter CRISPR ba­by scan­dal shut down work for years, Chi­na gene edit­ing com­pa­nies are restart­ing clin­i­cal tri­als

As­traZeneca pulls Covid-19 vac­cine glob­al­ly as the phar­ma sees 'no fu­ture com­mer­cial de­mand'

Med­ical Af­fairs: The Crit­i­cal Link Be­tween Sci­ence, Physi­cians and Pa­tients

Bit.bio finally details cell therapy pipeline for regenerative treatment, with initial focus on liver

After eight years with Sanofi, Frank Nestle departs as CSO, global head of research

Inside CVS Caremark’s move that broke Humira’s hold on the market

Teva to close additional manufacturing sites as it enters next phase of 'pivot to growth'

After CRISPR baby scandal shut down work for years, China gene editing companies are restarting clinical trials

AstraZeneca pulls Covid-19 vaccine globally as the pharma sees 'no future commercial demand'

Medical Affairs: The Critical Link Between Science, Physicians and Patients